Beyond KRAS mutation status: influence of KRAScopy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients

被引：0
|
作者：
Leonie JM Mekenkamp
Jolien Tol
Jeroen R Dijkstra
Inge de Krijger
M Elisa Vink-Börger
Shannon van Vliet
Steven Teerenstra
Eveline Kamping
Eugène Verwiel
Miriam Koopman
Gerrit A Meijer
J Han JM van Krieken
Roland Kuiper
Cornelis JA Punt
Iris D Nagtegaal
机构：
[1] Radboud University Nijmegen Medical Centre,Department of Medical Oncology
[2] Radboud University Nijmegen Medical Centre,Department of Pathology
[3] Radboud University Nijmegen Medical Centre,Department of Epidemiology, Biostatistics and Health Technology Assessment
[4] Radboud University Nijmegen Medical Centre,Department of Human Genetics
[5] University Medical Center Utrecht,Department of Medical Oncology
[6] VU University Medical Center,Department of Pathology
[7] University of Amsterdam,Department of Medical Oncology, Academic Medical Centre
来源：
BMC Cancer | / 12卷
关键词：
Cetuximab; KRAS Mutation; Copy Number Change; Poor Responder; Copy Number Gain;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Current status of treatment of metastatic colorectal cancer with special reference to cetuximab and elderly patients
    Pfeiffer, Per
    Qvortrup, Camilla
    Bjerregaard, Jon K.
    ONCOTARGETS AND THERAPY, 2009, 2 : 17 - 27
  • [22] Tumor KRAS Status Predicts Responsiveness to Panitumumab in Japanese Patients with Metastatic Colorectal Cancer
    Doi, Toshihiko
    Tahara, Makoto
    Yoshino, Takayuki
    Yamazaki, Kentaro
    Tamura, Tomohide
    Yamada, Yasuhide
    Yang, Bing-Bing
    Oliner, Kelly Smith
    Otani, Satoru
    Asahi, Daisuke
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (02) : 210 - 216
  • [23] Clinical outcome of panitumumab for metastatic colorectal cancer with wild-type KRAS status: a meta-analysis of randomized clinical trials
    Ibrahim, Ezzeldin M.
    Abouelkhair, Khaled M.
    MEDICAL ONCOLOGY, 2011, 28 : S310 - S317
  • [24] Targeting EGFR in metastatic colorectal cancer beyond the limitations of KRAS status: alternative biomarkers and therapeutic strategies
    Caiazza, Francesco
    Elliott, Louise
    Fennelly, David
    Sheahan, Kieran
    Doherty, Glen A.
    Ryan, Elizabeth J.
    BIOMARKERS IN MEDICINE, 2015, 9 (04) : 363 - 375
  • [25] RAS mutation testing in patients with metastatic colorectal cancer in French clinical practice: A status report in 2014
    Lievre, Astrid
    Merlin, Jean-Louis
    Sabourin, Jean-Christophe
    Artru, Pascal
    Tong, Sabine
    Libert, Lucie
    Audhuy, Francois
    Gicquel, Corinne
    Moureau-Zabotto, Laurence
    Ossendza, Roch-Anicet
    Laurent-Puig, Pierre
    Ducreux, Michel
    DIGESTIVE AND LIVER DISEASE, 2018, 50 (05) : 507 - 512
  • [26] Construction of prediction model for KRAS mutation status of colorectal cancer based on CT radiomics
    Cao, Yuntai
    Zhang, Jing
    Huang, Lele
    Zhao, Zhiyong
    Zhang, Guojin
    Ren, Jialiang
    Li, Hailong
    Zhang, Hongqian
    Guo, Bin
    Wang, Zhan
    Xing, Yue
    Zhou, Junlin
    JAPANESE JOURNAL OF RADIOLOGY, 2023, 41 (11) : 1236 - 1246
  • [27] The impact of primary tumor location on efficacy of cetuximab in metastatic colorectal cancer patients with different Kras status: a systematic review and meta-analysis
    Cao, De-Dong
    Xu, Hui-Lin
    Xu, Xi-Ming
    Ge, Wei
    ONCOTARGET, 2017, 8 (32) : 53631 - 53641
  • [28] KRAS mutation detection by high-resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer
    Malapelle, U.
    Carlomagno, C.
    Salatiello, M.
    De Stefano, A.
    De Luca, C.
    Bianco, R.
    Marciano, R.
    Cimminiello, C.
    Bellevicine, C.
    De Placido, S.
    Troncone, G.
    BRITISH JOURNAL OF CANCER, 2012, 107 (04) : 626 - 631
  • [29] Cetuximab Might Be Detrimental to Metastatic Colorectal Cancer Patients with KRAS Codon 12 Mutations
    Liang, Yi-Hsin
    Lin, Yu-Lin
    Liau, Jau-Yu
    Tsai, Jia-Huei
    Liang, Jin-Tung
    Lin, Been-Ren
    Hung, Ji-Shiang
    Tseng, Li-Hui
    Lin, Liang-In
    Chang, Yih-Leong
    Cheng, Ann-Lii
    Yeh, Kun-Huei
    ANTICANCER RESEARCH, 2015, 35 (07) : 4207 - 4214
  • [30] KRAS mutation detection by high-resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer
    U Malapelle
    C Carlomagno
    M Salatiello
    A De Stefano
    C De Luca
    R Bianco
    R Marciano
    C Cimminiello
    C Bellevicine
    S De Placido
    G Troncone
    British Journal of Cancer, 2012, 107 : 626 - 631
12345